Overview
Spherix’s coverage of the chronic kidney disease market monitors the dynamic and evolving landscape of CKD non-dialysis patient management. We closely track the competitive hyperkalemia market, along with the rapidly evolving diabetic kidney disease market, with specific deep-dives into SGLT2 inhibitors and their potential seismic market impacts. This research also delves into other disease states impacting CKD non-dialysis patients, such as metabolic acidosis and hypertension.
Services Available
Trending market evolution
Chronic Kidney Disease (US) – Diabetic Kidney Disease, Hyperkalemia, Hypertension, and Metabolic Acidosis - quarterly, n=100
Exploring the patient journey
Chronic Kidney Disease, Non-Dialysis (US) - n=1,000 patient charts
Chronic Kidney Disease, Non-Dialysis – PCP Perspective (US) - n=1,000 patient charts
Dialysis (US) - n=1,000 patient charts
Incident Dialysis (US) - n=650 patient charts
Prepping for the pipeline
Metabolic Acidosis (US)
Uremic Pruritus (US)
BENCHMARKING NEW BRAND PERFORMANCE
Kerendia (Bayer) in Diabetic Kidney Disease (US)
Gauging impact of disruptive events
Evolution of SGLT2 Inhibitors in DKD and Beyond
Multi-Specialty Impact of COVID-19 (US)
Renal Pipeline Tracker